Journals / Solunum / 2011 / Cilt: 13 - Sayı: 1

Miliary pulmonary metastases of malign pleural mesothelioma

Malign plevral mezotelyomanın miliyer akciğer metastazı

Journal
Solunum
Pages
41–45
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The patient died due to respiratory insufficiency at the 17th month of the diagnosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Malign pleural mesothelioma is characterized as an aggressive tumor that spreads widely on the pleura and invases directly thoracic structures.
📊
Key Findings & Data:Here, a 58 year-old woman having mixed type malignant pleural mesothelioma is being presented because she had miliary pulmonary metastases revealed in thorax CT at the 9th month of the diagnosis.
💡
Conclusion & Impact:The patient died due to respiratory insufficiency at the 17th month of the diagnosis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Malign pleural mesothelioma is characterized as an aggressive tumor that spreads widely on the pleura and invases directly thoracic structures. Miliary metastases are very rare in malignant pleural mesotheliomas. However, they can be observed at the time of diagnosis in some of the cases when the primary lesion is not detected and in some others in the later stages. For this reason one should suspect malignant mesotheliomas in the differential diagnosis when presentation is with diffuse miliary or micronodular pulmonary lesions. Immunehistochemical studies are helpful especially in differential diagnosis of other metastases when the primary lesion is not known. Here, a 58 year-old woman having mixed type malignant pleural mesothelioma is being presented because she had miliary pulmonary metastases revealed in thorax CT at the 9th month of the diagnosis. She was not a smoker and there was no history of asbest exposition. The patient died due to respiratory insufficiency at the 17th month of the diagnosis.

Özet

Malign plevral mezotelyoma, plevra yüzeyi geniş yayılım gösteren, torasik yapılara doğrudan invazyon yapan, agresif bir tümördür. Malign plevral mezotelyomada miliyer metastaz görülmesi çok ender olmakla birlikte, primer odağın saklı olduğu bazı hastalarda tanı anında, bazı hastalarda da ileri dönemde miliyer metastazlara rastlanabilmektedir. Bu nedenle, diffüz miliyer ya da mikronodüler pulmoner lezyonların varlığında, ayırıcı tanıda malign mezotelyoma da düşünülmelidir. İmmünohistokimyasal incelemeler, özellikle primer odağın bilinmediği diğer malign metastazlardan ayırıcı tanıda önemlidir. Mikst tipte malign plevral mezotelyoma tanısı almış, sigara ve asbest maruziyeti tanımlamayan, 58 yaşında kadın hasta, tanıdan 9 ay sonra saptanan miliyer akciğer metastazları nedeniyle sunulmaktadır. Hasta tanıdan 17 ay sonra malign mezotelyomaya bağlı solunum yetmezliği ile eksitus olmuştur.

🔖

Cite This Article

LEVENT, E., SARIMAN, N., SOYLU, A. C. (2011). Miliary pulmonary metastases of malign pleural mesothelioma. Solunum, Cilt: 13 - Sayı: 1, 41–45. https://ajindex.com/articles/314520

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Metintaş M. Plevra tümörleri. In: Mutlu B. Plevra hastalıkları. İstanbul:Turgut Yayıncılık ve Ticaret A.Ş, 2006:52-72
  2. Umeki S. Association of miliary lung metastases and bone metastases in bronchogenic carcinoma. Chest 1993;104;948-950
  3. Livasy CA, Tishko DJ, Maygarden SJ. Miliary pulmonary metastases from a clinically occult pleural mesothelioma. Ann Diagn Pathol 2003;7:249-253
  4. Ohishi N, Oka T, Fukuhara T, Yotsumoto H, Yazaki Y. Extensive pulmonary metastases in malignant pleural mesothelimoa. Chest 1996;110:296-298
  5. Özkan M, Tokat AO, Kavukçu Ş. Akciğerin metastatik tümörleri. Tüberküloz ve Toraks Dergisi 2003;51:207-215
  6. Huncharek M. Miliary mesothelioma.Chest 1994;106:605-606
  7. Pistolesi M, Rusthoven J. Malignant pleural mesothelioma. Update, current management, and newer therapeutic strategies. Chest 2004;126:1318–1329
  8. Gönlügür T, Gönlügür U. Lenfanjitis karsinomatoza. Genel Tıp Derg 2007;17:67-70
  9. Raoof S, Amchentsev A, Vlahos I, Goud A, Naidich DP. Pictorial essay: multinodular disease. a high-resolution CT scan diagnostic algorithm. Chest 2006; 129:805–815
  10. Uri AJ, Schulman ES, Steiner RM, Scott RD, Rose LJ. Diffuse contralateral pulmonary metastases in malignant mesothelioma. Chest 1988;93:433-434
  11. Tokat AO, Özkan M, Dizbay Sak S, Güngör A. Aksiller lenf nodu metastazı gösteren malign mezotelyoma: olgu sunumu. T Klin J Med Sci 2004, 24:425-427
  12. Craft PS, Reading MS, Jain S, O'Neil RA. Lymphangitis carcinomatosa complicating primary malignant peritoneal mesothelioma. Thorax 1996;51:552-553
  13. Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for management of malignant pleural mesothelioma. Eur Respir J. 2009, doi:10.1183/09031936.00063109
  14. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-2644
  15. Batırel HF. Malign plevral mezotelyomada trimodalite tedavi. Plevra Bülteni 2009;3:19-29
  16. Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008;26:1698-1704
  17. Özvaran MK. Yeni tedavi yöntemleri. Plev